PublishedDecember 18, 2024 Category Partner News Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
PublishedDecember 11, 2024 Categories eFlow Integrated PARI Publications eFlow Integrated – Aerosol Performance of a Novel Breath-Triggered Nebulizer
PublishedJune 26, 2024 Category Partner News Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
PublishedJune 12, 2024 Categories eFlow Integrated PARI Publications Optimising inhalation adherence and technique: The power of digital technology
PublishedApril 30, 2024 Category Partner News Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis